Evidence on the safety and efficacy of maximal cytoreductive surgery for advanced ovarian cancer is adequate to support using this procedure provided that standard arrangements are in place for clinical governance, consent and audit. Find out what standard arrangements mean on the NICE guidance page.
Patient selection should be done by a specialist gynaecological cancer multidisciplinary team, which may include surgeons from other specialities.
The procedure should be done by a team of surgeons with appropriate expertise. The procedure should only be done in accredited specialised units.
For auditing the outcomes of this procedure, the main efficacy and safety outcomes identified in this guidance can be entered into NICE's audit tool (for use at local discretion).